Crescent Biopharma After Year One: Steady Clinical Progress and a Measured Long Trade
Crescent Biopharma (CBIO) is a clinical-stage oncology company focused on small molecules and a PD-1 x VEGF bispecific (CR-001). After a sizable financing this summer, the balance sheet and multiple upcoming readouts reduce binary risk and create a tactical long opportunity. This trade idea lays out an entry at $14.00, a stop at $11.50 and a target…